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ABSTRACT
Three different cross-linking reagents were examined for their 
ability to link two antibodies together (anti-CD3 and anti- 
ovarian carcinoma) to produce functional 'bispecific' antibodies, 
-that is, antibodies capable of directing cytotoxicity towards 
ovarian cancer cell targets.
The cross-linking of antibodies by chemical means proved to be a 
difficult task.
The cross-linker SMPB, was found to be impractical for use on 
a routine basis, and resulted in a high loss of antibody due to 
the number of steps involved in the process.
SPDP and 0-PDM, on the other hand, did appear to produce 
'bispecific' antibodies, which were the correct size by gel 
filtration chromatography and which also produced 'positive' 
fluorescence by flow cytometry. Success was also achieved in 
producing antibodies capable of performing some directed 
cytotoxicity.
This investigation, however, also revealed a problem with the 
specificity of the antibodies and conjugates used.
Unfortunately because of time factors, further analysis of the 
linked antibodies, the conjugates and the successful linkage 
processes, could not be undertaken and many questions were thus 
left unanswered.
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3. ABBREVIATIONS
MHC Major Histocompatibility Complex
PHA Phytohaemaglutinln
TNF Tumour Necrosis Factor
NHS N-Hydroxysuccinimide
DMSO Dimethyl sulphoxide
DTT Dithiothreitol
HC Heteroconjugate
DTNB 5,5'-dithio bis(2-nitrobenzoic acid)
PBL ' Peripheral blood lymphocytes
PBMC Peripheral blood mononuclear cells
LGL Large granular lymphocytes
HCl Hydrochloric acid
EDTA Ethylene diaminetetraacetic acid
SBTI Soya Bean Trypsin Inhibitor
TEMED N,N,N',N'-Tetramethylethylenediamine
SDS Sodium dodecyl sulphate
dHgO distilled water
PBS Phosphate buffered saline
BSA Bovine serum albumin
FITC Fluorescein isothiocyanate
EBV Epstein-Barr Virus
PAGE Polyacrylamide Gel Electrophoresis
ELISA Enzyme-1 inked immunosorbent assay
4. INTRODUCTION
4.1 IMMUNOTHERAPY IN HUMAN CANCER
The current inadequacies of the established cancer treatments 
(i.e. surgery, radiotherapy and chemotherapy ) in controlling 
this devastating disease, reflects their lack of selectivity. 
In other words, the inability of these treatments to 
discriminate between normal and malignant tissues creates the 
serious problem of normal healthy tissues being destroyed in the 
process of treating the cancer. Indeed , the fact is that by 
the time many cancers are discovered, they have spread or 
metastasised to other locations in the patient's body and this 
makes it extremely difficult for any treatment regime to be 
effective in controlling or eliminating the cancer completely.
It is in this context that an immunological approach to cancer 
treatment provides such an attractive concept. This is because 
the immune system, the body's main natural defence mechanism is 
selective in its action, normally attacking only those agents 
such as bacteria and viruses for example, which it perceives as 
'foreign'. As such, it has been suggested that the spontaneous 
disappearance of tumours which has been noted in a few patients, 
is evidence for the involvement of the immune system in the fight 
against cancer [1]. This has ultimately led to the search for 
immunotherapies for cancer, that is, treatments designed to 
enhance the ability of the patient's own immune system to react 
against disease.
Although immunotherapy has progressed somewhat since the early 
days, it should be regarded as a valuable addition to the 
conventional therapies, rather than as an alternative. The 
complexity of the immune response to tumours means that a 
multilateral approach to immunotherapy is required and in 
practice this may involve several methods.
1. Active manipulation of the immune system seeks to enhance 
specific and/or non-specific mechanisms of host resistance by 
means of vaccination. This may involve infecting the tumour 
with viruses, coupling haptens to tumour surface antigens or 
fusing the tumour with cells of a different histocompatibi1ty 
type. Additionally, with non-specific immunization, a wide 
variety of reagents known as biological response modifiers (BRM) 
are employed, and these include bacterial products, synthetic 
molecules, hormones and cytokines. Early attempts to stimulate 
the immune system used vaccines prepared from bacteria such as 
Bacillus Calmette Guerin (BCG) or Corvnebacterium parvum. Some 
tumours in experimental animals were seen to shrink and in a few 
cases disappear entirely, and in humans the growth of certain 
kinds of tumours i.e. melanomas, was slowed, but the results 
were disappointingly inconsistent [2].
2. Adoptive immunotherapy (Cell Transfer therapy)involves the 
removal of immune defence cells from the cancer patient, 
followed by the re-introduction of these cells back into the 
patients bloodstream after they have undergone some sort of 
manipulation in vitro. This manipulation is designed to either 
'educate' the cells to react against the cancer, or to enhance 
their intrinsic ability to kill cancer cells [1]. It was 
discovered that in addition to causing T-helper cells and antigen 
stimulated cytotoxic T-cells to replicate. Interleukin 2 (IL-2) 
could actually stimulate certain lymphocytes to react and kill 
cancer cells. These were named Lymphokine activated killer 
(LAK) cells. Immunotherapy based on the administration of these 
cells has been beneficial in some cases, but the proliferation of 
lymphocytes in tissues can interfere with the function of vital 
organs. The appearance of these and other side effects led to 
further research and the discovery of tumour infiltrating 
lymphocytes (TIL's) - cytotoxic T-lymphocytes in the tumour which 
appeared to have the specificity that the LAK cells did not have.
Preliminary results indicated that TIL's extracted from a 
patient's tumour, propagated in vitro, and then reinfused back 
into the patient, could home to the tumour and result in its 
shrinkage. Although promising results have been obtained in some 
instances, the approach is limited to those cases where TIL's 
can be found [3].
3. Passive immunotherapy involves the transfer of anti-tumour 
antibody to patients in order to cause tumour regression or 
prevent tumour recurrence.
In 1975, when a method for producing a cell line capable of 
secreting a single species of antibody (monoclonal antibody) with 
the desired specificity to antigen was described, it was thought 
that this would provide the solution to successful tumour 
immunotherapy. This so called 'magic bullet' would be able to 
target tumour cells , destroying cancerous tissue, whilst 
leaving healthy tissue unharmed. Since that date numerous 
attempts have been made to exploit the specificity of these 
reagents for cancer therapy, but they have been largely 
unsuccessful in producing long term therapeutic effects on their 
own. This is because there are a number of difficulties 
associated with the use of antibodies for therapy, that are not 
found with the conventional treatments. Firstly, the
antibodies must be specific for all the neoplastic cells within 
tumours including the least differentiated tumour stem cells, 
and they must not react with any normal tissues or products 
within the host.
If an antibody-toxin complex is to be employed it must be lethal 
to the tumour cells alone, and attachment of the toxin to the 
antibody must be stable and not interfere with the ability of the 
antibody to interact with the tumour cells.
Finally, the antibody complex must be delivered to the host in 
such a way that it interacts effectively with all the tumour 
cells present but in doing so, the development of an immune 
response against the complex must be avoided. As such due to 
accessibility problems, even antibodies that do react 
preferentially with tumour cells, fail to reach the core of 
solid tumours in sufficient amounts to be effective [4].
Although the perfect antibody with absolute specificity for 
cancer cells has yet to be found, it has been possible to 
produce antibodies that are able to recognise antigens more
highly expressed on malignant cells than on corresponding normal 
cells, and this difference could prove to be useful in the
employment of monoclonal antibodies in immunotherapy. The 
antibodies are able to exert cytostatic effects if they bind to 
growth factor receptors, or interfere with their function but 
they tend not to be cytotoxic in their action without the aid 
of accessory mechanisms. The activation of secondary effector 
systems occurs when an intact antibody, bound to a tumour cell, 
binds to an Fc receptor on the surface of a macrophage, natural
killer (NK) cell, or a large granular lymphocyte (LGL). This
is referred to as antibody-dependent cellular cytotoxicity (ADCC) 
and results in an activation signal that stimulates exocytosis of 
cytolytic components from the effector cell onto the surface of 
the tumour cell. This method, however, relies on the
efficient recruitment of effector cells within the host which may 
not be present in sufficient numbers in solid tumours, be absent 
from immunoprivileged sites or be compromised by disease or 
previous therapy.
An alternative approach, would be to use monoclonal antibodies to 
target agents whose activity is not dependent on the immune 
system of the host. For example, radionuclides,
chemotherapeutic drugs and toxins all have inherent cytotoxicity 
but are not selective for the target cell unless directly coupled 
to the antibody.
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Radio-immunoconjugates, which decay to release beta-particles 
are able to destroy malignant cells at a distance of several cell 
diameters from the site of cell attachment, but have the 
disadvantage that normal tissues will be irradiated by conjugate 
present in the circulation. Antibody-drug conjugates, and the 
more potent immunotoxins, depend upon target antigen binding and 
Internalization, followed by the release of the agent within the 
cell by lysosomal digestion. This procedure is therefore
limited by the need for adequate internalization pathways for the 
transported cytotoxic agent [5].
Whatever approach to immunotherapy is employed, it should be 
noted that the majority of monoclonal antibodies that have been 
developed are of murine origin. Although they have been found
to be useful diagnostically in tumour imaging and in quantitating 
circulating tumour markers, they have been used with only 
limited success therapeutically. The main reason for this is 
the possibilty of the generation of anti-immune responses in 
the patient. This can result in the clearance of the
administered antibody, thus diminishing its use as a therapeutic 
agent. In addition, the development of host antibodies
restricts the administration of a second course of treatment and 
also prevents prolonged treatment.
The logical answer would therefore be to use human monoclonal 
antibodies for cancer therapy in the hope that they would be less 
immunogenic in patients, recognise more appropriate target 
antigens and trigger complement and antibody dependent cellular 
cytotoxic mechanisms more efficiently. However, the task of 
producing human monoclonal antibodies has proved to be a 
difficult one. The success of the procedure depends on an 
adequate supply of immune lymphocytes in an appropriate state of 
differentiation and proliferation, and effective methods for the 
immortalization, screening and cloning of these cells. This 
poses a problem because of the limitations of human monoclonal 
antibody production, with repect to donor immunization, 
lymphocyte availability and the suitability of fusion partners.
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In most cases, the lymphocytes for immortalization have been 
obtained from draining lymph nodes or peripheral blood, with the 
Immortalization procedure being carried out by cell fusion or 
more recently Epstein Barr Virus (EBV) transformation.
The latter procedure is that which is currently favoured, 
followed by fusion with either a human/mouse heteromyeloma or a 
mouse cell line such as SP2/0. Although antibody secreting cell 
lines have been generated, it is rare that the levels of
specific antibody produced are sufficient to be of use.
The limitations of human monoclonal antibody production
technology are thus of two kinds. Those relating to the 
production of the human antibodies in general, and those which 
are relevant to the development and therapeutic application of 
tumour monoclonal antibodies.
The cell lines themselves tend to be rather unstable, secreting 
low levels of antibody compared to murine cell lines. This 
could be due to a number of factors including the overgrowth by 
non-secreting cells, the loss of relevant regulatory and 
structural genes, and the inhibitory effects of contaminating 
micro-organisms. Even when an antibody does become available 
and it is highly specific for the tumour of interest, there are
still a number of factors which may limit its therapeutic
effectiveness. These have been summarised by Keith James [6] and 
are presented in Table 1.
As a result of the difficulties encountered in producing useful 
human monoclonal antibodies directly, considerable effort has 
gone into the alternative approach of 'Humanising' rodent 
antibodies by genetic engineering techniques.
TABLE 1 : FACTORS LIMITING THERAPEUTIC EFFECTIVENESS OF ANTIBODY
TARGET
Does not express tumour specific or other relevant target 
antigens (e.g. growth factor receptors )
Low target antigen expression
Variation in antigen expression within and between tumours 
Modulation/shedding of target antigens 
Inaccessibility of target antigens
ANTIBODIES
* Insufficient specificity, affinity and quantity
* Lack of information on optimum dose and route of 
administration
* Distribution and activity becomes modified by conjugation
HOST
* Individual variability in patients
* Localisation and degradation of antibodies in lungs etc
* Defects in host complement (C) and ADCC mechanisms
* Induction of immunosuppressive mechanisms by antibodies
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A variety of antibody molecules have been constructed including 
antibodies in which the entire rodent variable (V) region of both 
heavy (H) and light (L) chains, is linked to a human constant 
(C) region (chimaeric antibody). These should be less
immunogenic in patients, display the specificity of the original
rodent antibody and show improved Fc receptor mediated effector
functions.
There are also antibodies in which the polynucleotides coding for 
the Complementarity Determining Region (CDR) (hypervariable 
region) of human molecules have been replaced by equivalent 
polynucleotides from a rodent myeloma cell line secreting 
monoclonal antibody of the desired specificity. This method, 
known as CDR grafting, produces a molecule which is essentially 
human in nature, but which may have some loss of antibody
binding affinity [7,8].
Genetic engineering techniques have thus provided scientists with 
the means of gaining access to specific genes, which can be 
isolated, cloned and then expressed in an active form in 
bacterial or mammalian cells. The application of the
Polymerase Chain Reaction (PCR) to monoclonal antibody technology 
has also been important in allowing multiple copies of genes to 
be produced from a single cell.
For example, the binding region of the light (L) chain of 
immunoglobulin was found to bind without the aid of its heavy (H) 
chain. These single domain antibodies (dAbs) can be
manufactured by genetic engineering techniques and may be useful 
because of their small size, being able to penetrate tissue 
boundaries more efficiently than intact antibody molecules. 
They are also cleared from tissues and serum rapidly and although
this may limit their use as targeting agents, it can aid the
clearance of toxic drugs from the circulation [9].
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4.2 BISPECIFIC ANTIBODIES
In recent years there has been a great deal of enthusiasm 
directed towards the use of bispecific antibodies in tumour 
immunotherapy. These antibodies can be created by chemical 
cross-1 inking(heteroconjugates) or by fusing hybridoma cells, and 
they can be designed to simultaneously recognize two moitiés, 
such as antigens on target cells, and triggering molecules on 
cytotoxic cells [10].
As discussed earlier, there are a number of problems associated 
with the use of single antibody molecules for immunotherapy. 
Some of these however, may be overcome by targeting the cancer 
cells with effector cells via appropriate bispecific antibodies. 
This does not present a need for internalization as does the 
single antibody approach, and in addition, the biological 
activity of the system is apparent only after specific binding of 
the conjugate to the target cells that have provided the 
immobilizing surface that is necessary for T-cell activation. 
This means that no systemic T-cell activation will occur and to 
this extent the biological effect will be confined to the tumour 
[11].
For T-cells to mediate this targeted lysis they must have good 
killing ability and this requires their activation. T-cells 
express a number of different surface structures which are 
potential targets for antibody molecules, and that which is 
exploited most often is the CD3/TCR (T-cell receptor) complex. 
For T-cells to exhibit their lytic activity, this complex must 
bind specifically to the target antigen fragment in association 
with a Class 1 MHC molecule. Most cancer patients however, do 
not have significant numbers of these lymphocytes which 
specifically react with their tumour cells and it has proved 
difficult to isolate and expand these cells in vitro.
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Bispecific antibodies, however, circumvent the need for this 
specificity, and theoretically can be used to retarget all of 
the patients CTL's to destroy the cancer cells. Binding of an 
anti-tumour*anti-CD3 bispecific antibody to the TCR complex, 
results in the delivery of a signal via CD3 that activates the T- 
cell. This activation mimics that which occurs physiologically 
upon recognition of antigen by the TCR resulting in the 
triggering of the lytic machinery of the cytotoxic T-lymphocytes. 
Simultaneous binding of the tumour cell and activated T-cell 
results in the release of T-cell granule components close to the 
surface of the tumour cell. Pore-forming proteins are released 
producing holes in the tumour cell membrane, resulting in lysis 
of the tumour cell [12,13].
Investigators have been using bispecific antibodies of different 
types over the years in various systems, with varying success 
rates, and the information which has been generated from such 
experimentation has brought about an understanding of the 
mechanism by which they exert their effect, identifying the best 
methods of exploiting their potential.
Most studies have aimed to construct bispecific antibodies which 
are used to direct lysis of tumour target cells by effector 
cells, as measured by in vitro cytotoxicity assays. Many 
tumour cell lines including lymphoma, ovarian, colon, renal, 
melanoma, small cell lung and lung adenocarcinoma have been
shown to be lysed with appropriate bispecifics and effector 
cells, as have freshly isolated human tumour cells from renal, 
colon and ovarian tumour cells, and melanomas. The majority of
these studies used bispecifics linked by SPDP, in which the first
antibody was directed against tumour cell surface glycoproteins, 
and the second against the CD3 portion of the TCR/CD3 receptor 
complex. Perez et al [14] , in fact, showed that only
bispecifics containing anti-TCR components, could induce 
effector cells to lyse tumour cells in vitro, and that those 
containing antibody directed against other components of the T-
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cell did not promote lysis, even though they promoted 
effector/target cell formation. In addition targeting was shown 
to be specific, in that only human tumour lines and fresh tumour 
cells were lysed, but normal cells from a variety of tissues 
were not i.e. substitution of the anti-CD3 portion of the 
bispecific with anti-class 1 MHC antibody (W6/32) or substitution 
of the anti-tumour portion of the bispecific with irrelevant 
antibody, rendered it ineffective.
Effector cell populations which have been tested have included T- 
cell clones, donor and patient PBLs, TILs, monocytes, LGLs and 
macrophages. Many studies have used cytotoxic T-lymphocytes 
from' T-cell clones, but PBMCs from human donors have become 
more popular because they are much more readily available. Fresh 
PBL's however, are not as consistent a source of effector cells 
as are cultured PBL's that have been exposed to mitogens such as 
IL-2, PHA, anti-CD3 or combinations of anti-CD3, IL-2 and IL-4. 
This is because most lymphocytes in the periphery are resting 
cells incapable of mediating lysis. Pupa et al [15] noted that 
activation with PHA for 48 hours followed by 6-10 days in rIl-2 
culture was most appropriate for triggering hybrid-mediated 
lysis, and PBL's thus stimulated, lysed 75% and 16% of ovarian 
carcinoma targets (in the presence and absence of hybrid 
bispecific antibodies) respectively. Killing by anti-CD3 alone 
was minimal and there was no cytotoxicity in the absence of 
antibody. This, and the fact that F(ab)g fragments of antibody 
showed as efficient lysis as that of the intact molecule, would 
indicate that the killing observed was not due to ADCC.
Barr et al [16] also presented similar results using fusion 
hybridomas of anti-CD3/anti-colon carcinoma, in that cloned 
human T-cells and PBL's (after activation with rIL-2) produced 
high levels of specific lysis, and that very little bispecific 
antibody was required (less than Ipg/ml).
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Procedures for activating and expanding T-lymphocyte effector 
cells from peripheral blood of both normal and RCC patients were 
examined by Kerr et al [17]. Anti-CD3 and rIL-2 appeared to 
be the most effective combination for generating large numbers of 
lymphocytes, and lysis was found to be significantly augmented 
by increasing the length of incubation of the target and effector 
cells. For example, over 90% lysis was achieved at low E:T 
ratios by increasing the incubation period to 12 hours.
In systems which use anti-CD3 antibodies for activation of the 
lymphocytes, monocytes are usually required (binding to the Fc 
portion) in order to present the antibody to the T-cells and to 
provide necessary secondary signals. Serum IgG, however, was 
found to interfere with this binding and thus with cell 
activation [18]. When anti-CD3 was presented by means of an 
antibody heteroconjugate though, FcR involvement was avoided, 
and secondary signals could be supplied by anti-CD28 (which 
transmit progression signals in T-lymphocyte activation). Jung 
et al [18] showed that activation of monocyte depleted PBMC 
occurred with a mixture of anti-target/anti-CD3 and anti- 
target/anti-CD28, in the presence of melanoma target cells, and 
was effective at concentrations as low as 8ng/ml.
Heteroconjugate directed T-cell cytotoxic activity in vitro has 
been reported to be mediated by CD8+T-cells, whereas in vivo 
cytotoxicity appeared to involve both CD4+ and CD8+ cells, and 
prior exposure to IL-2. was not as important as that in vitro 
[19]. Thus the mechanism of in vivo antibody mediated anti­
tumour activity appears to be different from in vitro lytic 
mechanisms. It was shown that CD8“T-cells were inactive in a 
four hour cytotoxicity assay, but were able to block tumour 
growth in mice, and this suggests that there are two distinctly 
different anti-tumour effects mediated by heteroconjugate 
antibodies. The first effect is that of direct tumour cell 
lysis, and requires attachment of the target and effector cells.
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It is characterised by rapid anti-tumour activity (readily 
detected in a 4 hour Cr release assay) and does not induce lysis 
of bystander cells.
PBL's depleted of CD8+cells are incapable of mediating this type 
of lysis. Tumour growth inhibition, on the other hand, is 
measured by long in vitro assays or in vivo models. It is 
thought to be due to the release of slow acting factors such as 
TNFa or b, and interferon , which are produced from lymphocytes 
targeted with bispecific antibodies, and which have been well 
documented to block tumour growth. Inhibition appears to be 
induced by receptor cross-linking per se, for example in T-cells 
by anti-CD3 adsorbed on to microtitre plates. Cytokine release is 
important in that local release at the site of the tumour could
increase delivery to tumour cells while decreasing systemic
toxicities. In addition, cells that are in close proximity to 
the target could be indirectly growth inhibited, which is 
important in heterogenous solid tumours where some cells may 
express little or no target antigen, or be sterically 
inaccessible to effector cells.
On further examination of the T-lymphocytes, Mosmann and 
collaborators [20] showed that Th clones could be divided into 
two classes - those secreting helper factors such as 11-4 and IL- 
5 (Th2 clones) and those secreting inflammatory cytokines such as 
lymphotoxin, TNF- , IFN- and IL-2 (Thl clones). Targeted
lymphocytes are thought to block tumour growth by secreting 
factors which act directly on tumour cells and it is
possible that TNF- and IFN- indirectly or directly stimulate 
MHC non-restricted cytotoxic cells and assist in the generation 
of cytotoxic T-cells, both of which can lyse tumour cells. 
Therefore direct cell-mediated cytolysis could contribute to the 
blockage of tumour growth in vitro. As well as acting on tumour 
cells, secreted factors might also recruit and activate other 
anti-tumour effector cells such as Cytotoxic T-cells, NK cells, 
and macrophages in vivo. and may exert secondary effects such 
as causing blood supply to the tumour to be interrupted [19].
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The other factors to be taken into consideration in this system 
are the type of antibodies to be used, and the choice of method 
for linking such antibodies.
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4.3 CROSS-LINKING REAGENTS
When the coupling of two different proteins (A and B) is
required, it is important that the functional integrity of both 
proteins is retained after cross-linking. A suitable coupling 
reagent should, therefore, react in a controllable manner to
avoid intramolecular cross-linking and prevent the formation of
homo-conjugates (A-A and B-B) . There are a number of
commercially available cross-linkers which have been specifically 
designed for this purpose. They contain at least two reactive 
groups, usually at opposite ends of the molecule, and can be 
homobifunctional and covalently couple two identical functional 
groups, or heterobifunctional and react with two or more 
different groups.
Zahn, in 1955, was the first person to use chemical cross- 
linking reagents to study protein structures, and one such 
reagent DMA(Dimethyl adipimidate) is still widely used for this 
purpose. Homobifunctional imidoesters such as DMA, and in
particular DMS(Dimethyl superimidate) were popular throughout the
1970's, the former being used to cross-link lysine residues in
bovine pancreatic ribonuclease A.
In the 1970's, NHS esters were introduced as an alternative to
the imidoesters because they were reactive at physiological pH,
and had long half lives in aqueous media ie. DSS (Disuccinimidy1 
suberate).
These cross-linkers are used in a one step reaction procedure 
where the compounds to be coupled are added to the same buffer 
and the cross-linker is added to this mixture. This can be less 
efficient than other methods, but may be necessary if only
primary amines are available for cross-linking. This can
however result in unacceptable self-conjugation of proteins.
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Heterobifunctional cross-linkers however are designed to link 
proteins in a step-wise manner, promoting the preferential 
formation of heteroconjugates (A-B) [21] . Figure 1 shows the
components of a heterobifunctional cross-linker.
Examples of heterobifunctional cross-linkers are SPDP and SMPB 
(For chemical structures see Figures 2 and 3, respectively).
SPDP(N-succinimidy1 3-(2-pyridyldithio proprionate)) is the
'classic' cross-linker, which has been used extensively over the 
years in the construction of heteroconjugates. Although they do 
form^working immunotoxins in vitro, they have been found to be 
unstable in vivo. This is due to the breakdown of the 
introduced disulphide bond, and this can result in less toxin 
being available to destroy the targeted cells. Previous work in 
this laboratory has shown this to be true, and although SPDP is 
easy to use, the products tend to be unstable over storage and 
do not, therefore allow for reliable batch preparation. It was 
hoped to examine and to attempt to improve on this method of 
linking, and to compare it to other methods of interest to us.
SMPB(Succinimidy1 4-(p-maleimidopheny1)) is the extended chain
length analogue of MBS(m-maleimidobenzoy1 N-hydroxysuccinimide). 
This extension limits the interference caused by steric 
hindrances, and conjugates formed with SMPB have been shown to 
be more stable in serum than SPDP conjugates.
0-PDM(N .N '- 0 - phenylenedimaleimide) is another example of a 
bifunctional cross-linker and this has been used by Glennie et al 
[22] to produce functional bispecific antibodies (For chemical 
structure see Figure 4). The directed formation of bispecific 
antibodies in this case occurs by the linking of half-cysteine 
residues of two different Fab' species via tandem thioether 
bonds, to form F(ab')a bispecific molecules of approximately 
llOkDa.
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1. A primary amine reactive group such as N-hydroxysuccinimide
0
I I  >
R-C-O-N
0
0 0\
PH>7 11 ^
+ R ' —N H a  > R—C—N—R ' + HO—N
H
2. A thiol reactive group such as; a maleimide, halogen or 
pyridyl disulphide group.
(
a. Maleimides react specifically with free sulphydryls (cysteine 
residues) under siightly acidic to neutral conditions (pH 6.5-
7.5) .
R-N
pH>6.5-7.5 y
R ' —SH ----  ^ R—N,
%  H
V
\
5-R'
b. Halogens (iodoacetyl functions]) react with SH groups at 
physiological pH's.
0 0
pH>7.5 I
—C—CHa—I -F R ' —SH ----> R—C—(CHa»—S—R ‘ -h HI
BOTH OF THESE REACTIVE GROUPS RESULT IN THE FORMATION OF 
STABLE THIOETHER BONDS
FIGURE 1 : COMPONENTS OF A HETEROBIFUNCTIONAL CROSS-LINKER
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c. Pyridyl disulphides react with -SH groups to form a disulphide 
bond, releasing pyridine-2-thione as a biproduct. Conjugates 
prepared by this method can be cleaved using reducing reagents
R-S-S-
N'
+ R'-SH
pH>7.0 
 > R—S—S—R '
'N
H
3. The third component is the spacer arm or bridge which connects 
the two reactive ends and thus has an effect on steric 
hindrances. The bridge can also affect the stability of the 
reactive groups for example, the cyclohexane bridge of SMCC 
(succinimidy1 4-(N-maleimidomethy1)cyclohexane -T-carboxylate)
lends extra stability to the maleimide reactive group.
FIGURE 1 CONT/- ; COMPONENTS OF A HETEROBIFUNCTIONAL CROSS-LINKER
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0
II y
N S-S-CH2-CH2-C-O-N M.W. 312.4
FIGURE 2 ; STRUCTURE OF SPDP
p
N—0—C—CHg—CHg—CHs"
'/
M.W. 356.32
FIGURE 3: STRUCTURE OF SMPB
M.W. 268.2
FIGURE 4: STRUCTURE OF 0-PDM
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Functional studies have demonstrated that these bispecific 
heteroconjugates behave in a manner very similar to that 
described for bispecific IgG antibodies, but unlike the 
disulphide linked antibodies which can be susceptible to attack 
by trace amounts of thiol, the thioether linkage will ensure 
that these antibodies will remain intact.
The generation of conjugates using cross-linkers generally 
proceeds via a two-step reaction, as follows :
STEP 1 - The Amine Reaction
The protein chosen for reaction with the cross-linker should 
contain a primary amine, and should not contain free sulphydryl 
groups. The reaction buffer should also be free of extraneous 
sulphydryls and amines, and should be around pH 7.0-7.5. This 
prevents maleimide groups reacting with amines. NHS-ester 
cross-linkers have limited water solubility and have to be 
dissolved in a small amount of organic solvent, such as DMSO, 
before introducing the cross-linkers into the reaction mixture. 
The cross-linker/solvent forms an emulsion which allows the 
reaction to occur. The resulting protein becomes activated, 
with a sulphydryl moiety and can be isolated from the reaction 
mixture by gel filtration.
STEP 2 - The Sulphydryl Reaction
The protein required for the second reaction must contain a free 
sulphydryl group and buffers must be free of any sulphydryl 
containing compounds. A slightly acidic to neutral pH (6.5-7.5) 
is necessary for a maleimide reaction, whereas a neutral pH is 
sufficient for reactions involving halogens and pyridyl 
disulphides.
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Finally, the two proteins are mixed under appropriate buffering 
conditions, and the resulting protein conjugate can be isolated
from the reaction mixture by gel filtration (Pierce,[21]). For an
example of this type of conjugation using SPDP as the cross­
linker see Figure 5.
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1. REACTION OF PROTEINS A AND B WITH SPDP
S—CHa—CHa— C—0—N
\
4- B-NHz (OR A-NHa)
o
N
\ /
V
O H  oz:
I I I
S-S-CHa-CHa-C-N-BCOR A)) + HO-N,
OZ:
2. REACTION OF MODIFIED PROTEIN A WITH DTT
Q H
S-S-CHa-CHa
! DTTT 
V
0 H
I I  I
HS~CHa~CHa~C—N—A +
\
H
FIGURE 5: AN EXAMPLE OF A CONJUGAvTION USING PROTEINS A AND B
2'5
3. REACTION OF MODIFIED PROTEIN A WITH MODIFIED PROTEIN B
o
N
O H  O H
II I I I  I
-S-S-CHa-CHa-C-N-B + HS-CHa-CHa-C-N-A
\ / 
\ /
V
H 0
I I I
0 H
A-N-C-CHa-CHa-S-S-CHa-CHa-C-N-B HETEROCONJUGATE
A-B
H
FIGURE 5 CONT/-; AN EXAMPLE OF A CONJUGATION USING 
PROTEINS A AND B
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The major advantage in using heteroconjugates from cross-linking 
procedures, as opposed to the bispecific immunoglobulins 
secreted from hybrid hybridomas, is the ease with which they can 
be prepared. Cell fusion by contrast, tends to be a slow and 
unreliable process which has a number of limitations not least of 
which is the isolation of these antibodies from a heterogenous 
mixture of hybrid immunoglobulin molecules containing various 
mixtures of heavy and light chains [22].
With chemical linking, the antibodies can become aggregated 
producing a heterogenous population in which only some of the 
aggregates will be effective. The linking process may also lead 
to modulation of the TCR complex, rendering the T-cells useless. 
With the hybrid hybridoma technique, antibodies are homogenous, 
have a normal half life in vivo and are expected to induce little 
or no modulation of antigens. Because they retain their native 
configuration, they are theoretically more desirable for 
clinical applications than the chemical linkages but, only a 
small fraction of hybrids produce the desired hybrid antibody due 
to preferential isotypic assortment, low frequency of specific 
spleen cells and chromosome losses.
Mezzanzanica et al [23] compared SPDP-1inked HC's and hybrids of 
anti-target/anti-CD3 antibody using M0V18 antigen (reactive with 
human ovarian carcinoma). The binding reactivity of the HC and 
the hybrids was shown to be similar to that of the parental 
antibody, but maximum binding levels differed between the two. 
The latter had a lower level of binding and a lower percentage 
lysis, but exhibited a longer shelf life than the HC, due to 
the reduction of the disulphide bridge between the two monoclonal 
antibodies in the chemical pairing. The HC also had a low yield 
(approximately 5% of original).
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Canevari et al [24] also looked at SPDP-linked (divalent) and
hybrid bispecifics (monovalent), of anti CD3/M0V18 which also 
showed similar patterns of reactivity to that of the native
antibodies. Both promoted lysis by CTL's from T-cell clones or 
from activated PBl's, and there was no observed lysis with CTL's 
alone, or with uncoupled antibodies, and cytotoxicity was seen 
to be antibody concentration related.
Hybrid monoclonal antibodies tended to be superior to HC's as far 
as purification recovery was concerned, the HC yield again being 
5% of the initial volume, with cytolytic induction being
partially lost about 20 days after coupling. This problem might 
be alleviated by the use of different linking reagents that do 
not link through these chemical groups.
HC however, appeared to be more efficient at promoting lysis ie. 
50% lysis of OVCA line by 0.1pm HC and 6.6pm hybrid bispecific in 
the presence of CTL from T-cell clones. This lower efficiency 
in the latter example could be as a result of its monovalency or 
could also be due to the presence of parental antibody.
Hybrid antibodies tend to be more stable in storage and therefore 
are likely to be more stable in vivo, however, both methods are 
time and labour intensive techniques and need to be more 
efficient to produce large quantities for trials.
In addition to SPDP, Nitta et al [25] used DTNB as a cross­
linker, and combinations of SAMSA and SPDP to produce different
conjugates of 7S antibody.
A. DTNB - (F(ab)'2 ) lOO-llOkDa (Monomer) Yield 70-80%
B. SAMSA/SPDP - Monomer, dimer, trimer
220kDA (Dimer) Low yields
C. SPDP - Various polymeric forms of Fab
Main antibody 330kDa (Trimer)
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The monomeric form (A) appeared to be the most efficient at 
inducing cytolysis. The lower activity seen in the polymeric 
forms could be due to steric hindrances on antigen-antibody 
interaction.
Dimers and polymers of 7s antibody could be removed by FcR+RES 
cells such as NK cells and monocytes, and lost from the 
circulation.
Therefore, removal of the Fc region is necessary to ensure that 
the antibody is not immediately cleared, but remains bound and 
available on the target/effector cell surface until such time as 
the two surfaces are juxtaposed [22]. In addition, the non­
specific killing of FcR+cells is avoided.
F(ab)'2 fragments have proved more useful than their intact IgG 
counterparts because as small, high affinity molecules, they can 
cross capillary membranes and diffuse into tissue spaces more 
readily. Conjugates are also easier to prepare and appear to be 
more stable and less immunogenic in humans and so multiple 
courses of treatment can be considered if appropriate. In 
addition, their specific activity will be higher because more of 
the mass of each HC will be associated with antigen binding 
components, and studies have shown that Fc-free hybrids are only 
slightly less effective than their intact IgG counterparts 
[26] .
The model system for immunotherapy would therefore appear to be 
to use F(ab')a fragments of antibodies ( anti-target/anti-CD3 and 
anti-target/anti-CD28) which have been chemically cross-linked, 
and use these to target effector cells of CTL from T-cell clones 
or PBMC (activated by rIL-2) towards the tumour target. This is 
the system we wished to examine.
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5. MATERIALS AND METHODS
5.1 Cell Lines
OWmMl - Human ovarian cancer cell line growing as adherent cells. 
Cells are maintained by pouring off the old medium and replacing 
with fresh medium. Cells are split by incubating with 0.2% EDTA 
(in PBS) to detach them from the flask, spinning down and re­
seeding at the required count. This cell line has previously been 
shown to have characteristics associated with primary human 
ovarian tumours (Gallagher et al. [27]).
OVAN-4 - Human ovarian cancer cell line growing as adherent cells 
and cultured as above.
F14A/14C1 - B-cells from the lymph nodes of patients with ovarian 
cancer, immortalized by EBV. They grow in suspension and secrete 
antibody (IgG) against human ovarian cancer into the medium (F14A 
and 14C1 antibodies). When splitting or feeding cells, the 
suspension is spun down, the supernatant is retained and the 
cell pellet is resuspended in fresh medium at the required count.
0KT3 - Mouse hybridoma cells producing monoclonal antibody 
against the CD3 component of the T-cell (mouse anti-human 
antibody). Cell line grows in suspension and antibody is 
secreted into the medium and retained as above.
C0L0-32Q - Human colon cancer cell line, growing 50% suspension, 
50% adherent. When feeding, the cells in suspension are spun 
down and fresh medium is added, and they are incubated with PBS 
to remove them from the flask when splitting the cells.
All cell lines were maintained in Hams F-10 with 10%(v/v) Foetal 
calf serum, penicillin/streptomycin and 2mM L-glutamine.
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5.2 Antibodies
Rat CD3 : SHL45.6 bivalent CD3 antibody generated as a biproduct
of the purification of monovalent CD3. FPLC purified.
Supplied by Mike Clark (Cambridge)
W6/32 : Anti-class 1 MHC antibody
595 : Anti-human ovarian cancer antibody(Supplied by M.Pimm,
Nottingham)
505 : Anti-colonic cancer antibody(Supplied by M.Pimm,
Nottingham)
5.3 Preparation of IgG and F(ab')g fragments
IgG from human serum or cell supernatants was isolated by 
adsorption to a Protein A sepharose column.
F(ab')a fragments were prepared by digestion of the IgG (at 
approximately lOmg/ml) in O.IM sodium acetate (pH 4.2) with pepsin 
at 0.3mg/ml, for 18 hours at 37°C. The F (ah') a was then 
separated from the digest mixture by gel filtration on a column 
of Ultrogel Aca34 equilibrated in 0.2M Tris/HCl(pH 8.0) 
containing lOmM EDTA.
Alternatively, fragments could be purified by protein A affinity 
chromatography and a Centricon-30 microconcentrator.
5.4 Bicinchoninic Acid (BCA) Assay
Solution A - contains bicinchoninic acid, sodium carbonate, 
sodium tartrate and sodium bicarbonate in 0.1 N sodium hydroxide 
(pH 11.25)
Solution B - Copper (II) sulphate pentahydrate 4% solution 
containing 4% (w/v) cupric sulphate.SHaO.
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Protein determination reagent (1ml) consisting of 1 part solution 
B to 50 parts solution A was added to 0.05ml sample in a test- 
tube and incubated for 30 minutes at 37°C. The tubes were then 
cooled to room temperature and three aliquots of 0.1ml from each 
were measured for absorbance at 562nm. The absorbance values 
were compared to those of a standard curve (series of doubling 
dilutions of BSA, starting at lOmg/ml) and the concentration of 
protein in each sample was determined.
5.5 Preparation of Bispecific antibodies using 0-PDM
Bispecific antibodies were prepared according to the method 
described by Glennie et al(1987).
F(ab')z (see procedure 2.3) from the two antibodies of interest 
at approximately lOmg/ml in 0.2M Tris/HCl buffer (pH 8.0) 
containing lOmM EDTA (Buffer A), was reduced by the addition of 
20mM 2-mercaptoethanol (2-ME), for 30 minutes at 30°C. Both 
samples of reduced Fab' (Fab'sw) were then chilled to 4°C, a 
temperature which was maintained throughout the remainder of the 
procedure, before running through Sephadex G-25, equilibrated 
in 50mM sodium acetate (pH 5.3) containing 0.5mM EDTA (Buffer B ) . 
A half volume of 12mM 0-PDM in chilled dimethy1formamide was 
then added to one of the antibodies for 30 minutes after which 
the maleimidated Fab' (Fab'm a l ) was separated from other solutes 
by passage through Sephadex G-25 equilibrated in Buffer B. The 
product was then added immediately to the other antibody and 
concentrated using a Centriprep-30 device.
After an incubation period of 18 hours the pH of the reaction
mixture was adjusted to 8.0 with IM Tris/HCl (pH 8.0) before
reducing with 2-ME at a final concentration of 20mM for 30
minutes at 30°C, and alkylating with 25mM iodoacetamide.
Finally, the bispecific F(ab')z was separated from other 
products of the reaction mixture by passage through Ultrogel
Aca34, equilibrated in Buffer A.
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NOTE
1. After maleimidation of one of the antibodies, no free 
sulphydryl groups should be present, indicating that the 
reaction with 0-PDM has been completed. This can be confirmed 
by reacting with Ellman's reagent, which produces a yellowing 
reaction in the presence of sulphydryl groups (See determination 
of sulphydryl content).
2. The final reduction and alkylation step is designed to remove 
any residual products, including F(ab')2 monomers which may have 
formed.
3. The major product of interest, the bispecific F(ab')2 should 
elute at approximately llOkDa molecular weight.
5.6 Preparation of Bispecific antibodies using SPDP
Bispecific antibodies were prepared according to the method 
described by Karpovsky et al [28]. The detailed pocedure for 
one preparation was as follows :
Intact Rat 0KT3 antibody (4ml, Img/ml in PBS) and Mouse anti- 
ovarian antibody (1.3ml, 3mg/ml in PBS) were each concentrated to 
approximately 0.1ml and then made up to 1ml with O.IM sodium 
phosphate O.IM sodium chloride (pH 7.5) [Coupling Buffer]. Both 
antibodies were then incubated separately with 3-fold molar 
excess of SPDP (0.1ml of 0.24mg/ml solution of SPDP in ethanol 
was added to each sample) for 30 minutes at room temperature.
The anti-ovarian antibody (595) was passed through a G-25 column 
to allow exchange into coupling buffer to occur.
The rat 0KT3 antibody was passed through a G-25 column 
equilibrated in O.IM sodium acetate/0.IM sodium chloride (pH
4.5), before adding dithiothreitol (DTT) to a final 
concentration of 0.02M. After 30 minutes at room temperature, 
the antibody was passed throught a G-25 column equilibrated with 
coupling buffer and immediately added to the 595 antibody.
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After incubating overnight at room temperature, iodoacetamide 
was added to the reaction mixture before it was passed through a 
column of Ultrogel Aca34 equilibrated in PBS.
NOTE
The major product of interest, bispecific (IgG)2 should elute at 
approximately 300kDa molecular weight for intact IgG and 220kDa 
for (F(ab')2)2 bispecifics.
5.7 PREPARATION OF BISPECIFIC ANTIBODIES USING SMPB
Bispecific antibodies were prepared according to the method 
described by Pierce [21].
This cross-linker can be used to link intact antibodies together, 
as well as F(ab')2 fragments of antibodies.
Antibody A was dialysed against 0.05M phosphate buffer (pH 8.0) 
whilst Antibody B was dialysed against 0.05M phosphate buffer 
(pH 7.0).
SMPB dissolved in DMSO was added to Antibody A at a molar ratio 
of 1:40 SMPB, and stirred for 30 minutes at room temperature. 
The antibody was then passed through a G-25 column, and added 
to Antibody B, for incubation with stirring at room temperature 
for approximately 3 hours. The mixture was then concentrated 
using a Centriprep-30 device and passed through a column of 
Ultrogel Aca34, equilibrated in PBS.
;n o t e
In this reaction scheme, the heterobifunctional cross-linker 
reacts with a primary amine in the first step (Reaction with 
Antibody A), and a free sulphydryl group in the second (Reaction 
'Of cross-1inker-A with Antibody B).
iSulphydryl groups may be generated from primary amines on the 
.antibody molecule using a protein modification reagent such as 
SATA (See generation of sulphydryl groups).
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5.8 GENERATION OF SULPHYDRYL GROUPS USING SATA 
(N-succinimidvl S-Acetvl thioacetate)
Immediately before the reaction, SATA(13-15mg) was dissolved in 
1ml DMSO. The IgG to be derivatized should be in 50mM sodium 
phosphate (pH 7.5) containing ImM EDTA, at a concentration of 
60uM, before reacting with the SATA solution (0.01ml SATA/lml IgG) 
for 30 minutes at room temperature. The reaction mixture was 
then passed through a G-25 column to recover the IgG fraction. 
The sulphydryl groups are introduced in a protected form and may 
be made free by reacting the antibody with deacetylation solution 
(50mM sodium phosphate, 25mM EDTA, 0.5M Hydroxylamine 
hydrochloride (pH 7.5)(0.Iml/ml IgG)) for two hours at room 
temperature. The protein was then passed through a G-25 column 
to remove unreacted and hydrolysed SATA, along with 
hydroxylamine and its biproduct. The buffer used should contain 
ImM EDTA to help protect the free sulphydryl groups. (For 
the reaction between SATA and a protein see Figure 6).
5.9 DETERMINATION OF -SH CONTENT WITH ELLMAN'S REAGENT (DTNB)
Samples can be assayed for sulphydryl content by reacting with 
Ellman's reagent in O.IM sodium phosphate (pH 8.0). A sample of 
the protein (0.1ml) and 0.1ml of Ellman's reagent solution was 
added to 5.0 ml of O.IM sodium phosphate buffer (pH 8.0) and 
allowed to react at room temperature for 15 minutes. A yellow 
colour is formed in the presence of free sulphydryl groups. The 
sulphydryl content can be determined by preparing a standard 
curve using a series of concentrations of cysteine hydrochloride 
monohydrate which are treated in the same manner as the protein 
samples. The absorbance at 412nm of each protein sample is 
measured and the sulphydryl content calculated via the standard 
curve. By comparing the absorbance at 280nm of the protein 
solution to its extinction co-efficient, the number of moles of 
sulphydryl per mole of protein can be determined.
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1. REACTION OF SATA WITH A PROTEIN PRIMARY AMINE, FORMING AN 
ACETYLTHIOACETYLATED PROTEIN AND N-HYDROXYSUCCINIMIDE
ro 0 0
I I  I I
N-O-C-CHz-S-C-CHa + PROTEIN-NHz
:0 SATA
(231.22) \ /
\ /
V
0 0
I I  I I
PROTEIN-N-C-CHz-S-C-CHa + N-OH
DEPROTECTION OF THE SATA MODIFIED PROTEIN WITH HYDROXYLAMINE 
FORMING A PROTEIN WITH A FREE SULPHYDRYL AND ACETYL 
HYDROXYLAMINE.
0 0
I I  I I
PROTEIN-N-C-CHz-S-C-CHa
! NHzOH 
V
0 0
II II
PROTEIN-N-C-CHz-SH + CHa-C-N-OH
H
FIGURE 6: REACTION SCHEME OF SATA
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5.10 GEL FILTRATION CHROMATOGRAPHY
Sephacryl S-200 or Ultrogel Aca34 columns were used to separate 
reaction mixtures depending upon the estimated size of molecule 
to be isolated.
Sephacryl is a rigid gel capable of good resolution at 
comparatively high flow rates, and each bead consists of a 
mixture of agarose and acrylamide. The gel used in this 
instance excludes molecules above 200kDa molecular weight.
Ultrogel is composed of a homogenous network of polyacrylamide 
and agarose in bead form and large columns should be run at low 
flow rates for maximum resolution.
All buffers used contained a small amount of azide to prevent 
column degradation.
Before use, the columns were calibrated using a series of known 
molecular weight standards, allowing at least one void volume of 
PBS to pass through between each sample. Standards were 
dissolved in PBS containing a small amount of glycerol to 
increase the density (see Table 2).
Molecular weight determinations of the unknown proteins were made 
by comparing the ratio of Ve/Vo for the protein to that of the 
standards (Ve - elution volume of sample, Vo - void volume 
(volume of effluent required for the elution of Blue Dextran)).
A calibration curve was then prepared by plotting the logarithms 
of the known molecular weight standards versus their respective 
Ve/Vo values.
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TABLE 2 : MOLECULAR WEIGHT STANDARDS
STANDARD MOLECULAR WEIGHT
Blue Dextran 2*10* K
Urease 270 K
B-amylase 200 K
Alcohol dehydrogenase 180 K
Bovine serum albumin 66 K
Carbonic anhydrase 29 K
SBTl' 20.1 K
Cytochrome c 12.4 K
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5.11 SDS-PAGE
This system uses TEMED and ammonium persulphate to initiate 
polymerization of the acrylamide gels, and SDS to dissociate all 
proteins into their individual polypeptide sub-units. A
discontinuous buffer system is used to give better resolution 
than a continuous buffer system and involves loading the sample 
onto a large pore 'stacking' gel polymerized on top of a small 
pore 'resolving' gel.
Gels of 0.75 mm thickness and 10%( with respect to the acrylamide 
monomer) were prepared in an LKB 'Midget' casting apparatus, and 
stored at 4®C in electrophoresis buffer (1*) until required. 
Samples at 0.2mg/ml in loading buffer (without mercaptoethanol) 
were heated at approximately 60°C for 1 minute, cooled, and 
either stored at -20^C or loaded onto a gel (15ul aliquots). 
Molecular weight markers were also included for reference 
purposes (see 2.12).
Each gel was run at 10mA, until the bromophenol blue dye front 
was just off the bottom of the gel. The gels were then removed 
from the gel plates and processed as required.
5.12 5DS-M0LECULAR WEIGHT MARKERS
A vial containing 3.0mg of a lyophilised mixture of proteins 
(SIGMA)(See Table 3) was reconstituted in 1ml Sample buffer 
(made up from sodium phosphate monobasic(0.34g), sodium phosphate 
dibasic(1.02g), SDS(l.OOg), 2-Me(1.00ml), Bromophenol
blue(0.015g), Urea (36.00g) in 100ml distilled water.
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TABLE 3 : SDS-MOLECULAR WEIGHT MARKERS
PROTEINS MOLECULAR WEIGHT(Da)
Myosin 205 K
B-galactosidase 116 K
Phosphorylase b 97.4 K
Bovine serum albumin 66 K
Egg albumin 45 K
Carbonic anhydrase 29 K
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5.13 C00MA5SIE BLUE STAINING
The gel was placed in staining solution (0.625g bromophenol blue, 
40%(v/v) methanol, 7%(v/v) acetic acid, dHzO to 250ml) 
overnight. The solution was then removed and replaced with 
destaining solution (30%(v/v) methanol, 10%(v/v) acetic acid) 
with agitation. This was changed at regular intervals until the 
desired level of staining was obtained.
5.14 SILVER STAINING USING THE WRAY METHOD
After fixing the gel in 50% reagent grade methanol (with 0.1ml 
formaldehyde/100ml methanol), for at least one hour, the 
silver stain (prepared by adding 0.4g silver nitrate (in 2.0ml 
water) dropwise to a solution of ammonia, [ 11ml of 0.36% sodium 
hydroxide, 1.0ml 14.8M ammonium hydroxide], with constant
vortexing and increasing to 50 ml volume with distilled water) 
was added for 15 minutes with constant gentle agitation. The 
stain was then removed and the gel washed twice in dHaO for 10 
minutes each wash. The gel was then developed by immersion in 
citric acid(1ml)/formaldehyde(0.1ml) solution in 200ml water. 
The bands appeared in not less than 10 minutes and not more than 
15 minutes, after which the gel was washed in water and placed 
in 50% methanol overnight, and then stored in dHzO.
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5.15 SILVER STAINING USING ALTERNATIVE METHOD
After prefixing the gel in 50% methanol/10% acetic acid for 30 
minutes, followed by 30 minutes in 5% methanol/7% acetic acid, 
fixing was achieved by soaking the gel in 5% gluteraldehyde 
solution for 30 minutes. The gel was then either washed 
overnight in dHsO, (or washed six times at 15 minutes each wash 
in dHsO), followed by 30 minutes in DTT(5ug/ml). Without 
rinsing, this solution was poured off and 0.1% silver nitrate
solution was added for 30 minutes. A small amount of dHzO was
used to wash the gel once, and then developer (0.05ml 
formaldehyde in 100ml sodium carbonate (3%)) was used to wash
the gel twice The gel was stained to the desired level with
developer, and the reaction was stopped with 5m1 of 2.3M citric 
acid, agitated for 10 minutes and then rinsed and stored in 
dHzO.
5.16 CYTOTOXICITY ASSAY 
Preparation of Target cells
Tumour target cells were removed from culture flasks by 
incubating for a short time with 0.2% EDTA (in PBS) and washed in 
RPMI-1640 medium. The cell pellet was incubated with 3MBq Cr=i 
for approximately 1 hour at 37°C, washed (2*10 minutes) and 
resuspended in 10ml RPMI-1640. After a second hour incubation 
period, the cells were washed (2*10 minutes), resuspended in 
2m1 medium and counted.
Preparation of Effector cells
Human peripheral blood mononuclear cells isolated from
heparinized blood by density gradient centrifugation, were
washed, resuspended in RPMI-1640 and counted.
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Both cell volumes were adjusted accordingly before adding to the 
test plate.
Target cells were added to all test wells in a 96-well U-bottomed 
microtitre plate, together with combinations of antibody 
conjugate and effector cells. The plates were incubated at 37°C 
(with 5% CO2 ) for 4 hours and 24 hours. Supernatants (0.1ml) 
were collected and the amount of Cr®^ was measured. Percent 
specific cytotoxicity was calculated by the standard formula -
% CYTOTOXICITY = cpm Exp - com Soon *100
cpm Max - cpm Spon
The maximum release values (cpm Max) were obtained by adding an 
equal volume of TritonX-100 to the target cells.
Spontaneous release values (cpm Spon) were determined by 
measuring the radioactivity released during incubation of target 
cells in media alone.
Tests were also included that contained PBS instead of medium as 
another control.
Triplicate samples for each data point were measured and the mean 
values calculated (cpm Exp).
5.17 PREPARATION OF PBMC FOR FLOW CYTOMETRY
Human PBMC were isolated from normal healthy heparinized blood by 
Ficol1-Hypaque density centrifugation. The cells were then 
washed twice with PBS (with 0.2% BSA), resuspended in 5mls PBS, 
and counted.
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5.18 FLOW CYTOMETRY
Binding of the antibody conjugates (or control molecules) to the 
target cells (and to PBMC) was monitored by Flow Cytometry using 
the EPICS Profile II.
Cells or PBMC (at approximately 1 million per test) were washed 
with PBS (containing 0.2% BSA) and exposed to 0.1ml of 
appropriate antibody sample (or control) for 30 minutes on ice. 
The cells (or PBMC) were then washed with PBS (2*10 minutes) and 
treated with 0.1ml of the appropriate labelled secondary antibody 
(For example, F(ab')z Rabbit Anti-mouse IgG FITC conjugate), for 
30 minutes on ice. After a final washing stage (2*10 minutes) 
to remove any unbound reagents, the samples were resuspended in 
b.3ml wash buffer before examining for fluorescence.
All labelled antibodies were supplied by Serotec or Sigma.
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6. RESULTS AND DISCUSSION
This project was proposed to examine the best and most convenient 
methods of chemically linking two different species of monoclonal 
antibody, using bifunctional reagents, and subsequently to 
compare the conjugates for storage stability, ease of 
preparation, and yield and activity of final product.
The two monoclonal antibodies which we were interested in joining 
initially were 0KT3 and 14C1 or F14A. The former antibody
reacts with the CD3/TCR complex on T-lymphocytes, as described 
earlier, whilst the latter are human monoclonals which have 
been reported as showing histological specificity towards human 
ovarian epithelial carcinomas, being the result of EBV- 
transformation of lymphocytes obtained from the involved lymph 
nodes of ovarian cancer patients [29]. It was thought that 
conjugates of this type (anti-CD3 * anti-14Cl/F14A) could be 
potentially useful in the immunological targeting of ovarian 
cancer, because of the highly localised nature of the disease 
(i.e. the métastasés usually remain within the peritoneal 
cavity). In fact an ovarian cancer associated membrane antigen, 
14C1, has been defined using the same named human monoclonal 
antibody. The expression of the antigen was highly restricted 
to ovarian epithelial tumours, particularly of the clear cell 
carcinoma and serous or mucinous cystadenocarcinoma, of which 
88% were positive, whereas a wide range of other normal and 
malignant tissues did not express the 14C1 antigen [30]. This 
antigen may therefore represent a potent target for both active 
and passive immunotherapy in the post surgical treatment of 
ovarian cancer.
The cel 1-lines OWmMl, previously identified as bearing the 
antigen recognised by F14A, and OVAN-4, which has a greater 
expression of the F14A antigen, were chosen as the 'target' 
cel 1-lines for our system, and were maintained as described in 
method 5.1.
45
The first stage of the procedure was concerned with obtaining and 
purifying the chosen antibodies. The antibodies described above 
were secreted in cell culture from continuous cel 1-lines, 
maintained within the laboratory, and were purified as described 
in the methodology.
Quantitation of the purified antibodies was carried out by a BCA 
assay according to method 5.4, which measured protein content 
(it was assumed that the antibody was the only protein present). 
This method was rapid and very straight forward producing colour 
changes in the presence of protein.
Because cross-linking procedures operate more efficiently in 
concentrated protein solutions, it was necessary to concentrate 
the antibody solutions using Centriprep-10 devices (Amicon). 
Each device was able to concentrate a maximum of ISmls of 
solution to approximately 1ml volume, operating by
centrifugation (N.B. Centricon-10 devices could be used to 
concentrate smaller volumes (i.e. Imls) to approximately 0.1ml 
volume). The '10' indicates the cut-off point - anything
smaller than lOKDa molecular weight passed through the membrane, 
leaving larger molecules in the concentrate.
The 14C1 and F14A antibody cell line supernatants were normally 
combined and produced approximately 0.Img/ml IgG per flask every 
four days. The 0KT3 antibody had a lower yield producing 
approximately O.OOlmg/ml per flask every four days. Therefore, 
accumulating sufficient amounts of antibody to be of use in 
experiments could sometimes take a number of weeks.
Before attempting the cross-linking reactions with the antibodies 
of interest, it was necessary to follow the procedure through 
with irrelevant antibodies.
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CROSS-LINKING WITH Q-PDM
The first cross-linker to be examined was 0-PDM. Sheep and human 
IgG's were used in the reaction according to the method 
described in 5.5 , as this method has been successfully carried 
out by Glennie et al [22] and is carefully detailed. The final 
digestion mixture was passed through a column of Sephacryl (S- 
200), linked to a monitor and chart recorder, which produced a 
trace of the products as they passed out of the column. The
volume at which each peak reached its maximum was recorded (Ve). 
The ratio of Ve/Vo (void volume) was then read from the standard 
curye (see method 5.10) to obtain an estimate of the molecular 
weight of the recovered product. In this instance the products 
were of very low molecular weight i.e. 2,000 Daltons, suggesting 
that the complex had either degraded, perhaps due to too rapid a 
passage through the column or an incorrect pH of the elution 
buffer, or the antibodies had not conjugated initially. At 
various stages in the linkage procedure, samples of the products 
were taken for SDS-PAGE (methods 5.11 and 5.12), to provide a 
visual assessment of their molecular weights. This would give 
an indication of the size of the complex throughout the 
experiment. Unfortunately, the silver staining method (Wray, 
method 5.14) which had previously been carried out successfully 
did not produce good staining. Changes were made in the
protocol to use bottled water instead of distilled water as the
latter was thought to contain chloride ions which may have 
interfered with the staining procedure. This did not make any 
difference and an alternative method (5.15) was attempted which 
gave slightly better staining but the gels could still not be 
read accurately. Coomassie Blue was then employed to stain the 
gels (according to method 5.13)(results not shown). It was less 
sensitive than the silver nitrate method, but any bands present 
were easily read against control molecular weight markers. This 
confirmed the earlier results that the molecular weights of the 
products were very low and therefore also confirmed that the
linkage had not been successful.
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CROSS-LINKING WITH SMPB
Consequently, another cross-linker, SMPB, was used to link the 
F(ab')2 fragments (see method 5.3 for preparation) of human IgG 
(5mg total) and sheep IgG (lOmg total), (according to method 
5.7). The resulting product, after passage through sephacryl 
S-200, produced a major peak corresponding to approximately 
ISOKDa. This was slightly less than was expected for this type 
of linkage (i.e. F(ab')2 * F(ab')2 should be about 220KDa) but it
is possible that the light chain of one of the antibodies may 
have become detached at some stage in the linkage process.
This procedure was therefore carried out with the mouse 0KT3 and 
human 14C1/F14A antibodies. The resulting mixture produced the 
trace observed in Figure 7 after S-200 column chromatography. 
The first product (Peak 1)approximated to 230KDa molecular weight 
and the second (Peak2)to 5KDa, suggesting that the former could 
be a bispecific antibody according to its size. The products 
were then run on SDS- polyacrylamide gels and stained with 
coomassie blue (results not shown). This appeared to confirm the 
molecular weight of the product as approximately 230KDa 
(Designated Product A) and the linkage was repeated with similar 
results (Product B), but it was necesssary to confirm the 
composition of the products by other methods.
Martin Glennie et al [22] examined their bispecific products by 
double diffusion analysis in agar (Ouchterlony and Nilsson, 1973) 
to visualize the individual components, and this was attempted 
with the SMPB bispecific products A and B.
Four 1.5% agar plates were set up according to Figure 8 and 
incubated in a 'moist box', until precipitin lines were observed. 
In plates 3 and 4 there were no precipitin lines formed between 
product B and either of the expected components (i.e. anti-human 
IgG and anti-mouse IgG), and whilst in plates 1 and 2, product 
A did produce precipitin lines with both anti-human IgG and anti­
mouse IgG, the 14C1/F14A and 0KT3 antibodies reacted with their 
own antigens and with the opposite antigens (i.e.human ovarian 
antibody reacted with anti-mouse IgG, and mouse 0KT3 reacted 
with anti-human IgG).
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FIGURE 7: TRACE OF SMPB LINKAGE PRODUCTS AFTER 
PASSAGE THROUGH S-200
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FIGURE 8: OUCHTERLONY REACTION
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This observation led us to believe that the cell lines had become 
cross-contaminated. This was , however, ruled out by ELISA 
testing of the cell-line supernatants, and therefore the 
reaction in the ouchterlony was probably due to cross reactivity 
between antigens and antibodies, and no definite conclusions 
about the components of the 'bispecific' antibodies could be 
made.
It was therefore decided to employ Western Blotting in an attempt 
to detect the presence of both human and mouse components in the 
'bispecific' products. Products A and B, were subjected to SDS- 
PAGE and then blotted onto nitrocellulose. The mouse 0KT3 and 
human 14C1/F14A antibodies were also put on individually to 
ensure that the conjugates were specific and active for each 
component. The gel was stained to ensure complete transfer of 
all proteins, and the nitrocellulose then probed with anti­
mouse Fab' conjugate. This procedure was repeated with another 
gel and the nitrocellulose probed with anti-human Fab' conjugate. 
The latter conjugate resulted in the appearance of a band in the 
lane in which the 'bispecific' products had run and in the lane 
containing anti-ovarian antibody as expected. However, the 
anti-mouse conjugate also produced these results and there was no 
band apparent in the lane in which the 0KT3 antibody was present. 
Again there would appear to be the problem of cross-reactivity, 
and this method was therefore considered unsuitable for examining 
any 'bispecific' products.
The products of both linkages however, were combined and 
concentrated (1.7mg total) and retained for use in later 
experiments (Designated SMPB A-B).
For the directed formation of bispecific antibodies using SMPB, 
the first antibody in the reaction should contain a primary amine 
for reaction with the cross-linker, and the second antibody 
should contain free sulphydryl groups. This was not the case on 
our previous attempts at linking the antibodies and therefore it 
is unlikely that the product recovered was in fact a 'bispecific' 
antibody.
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The molecular weight observed initially which had led us to 
believe that the linkage had worked successfully, may perhaps 
have been due to a F(ab')3 molecule of one of the antibody 
species.
Sulphydryl groups can however, be introduced into proteins by the 
agent SATA, according to the method described in 5.8. The 
sulphydryl group is introduced in a protected form allowing it to 
be stored for long periods of time without degradation of the 
groups. Deprotection is then achieved in a subsequent reaction 
with Hydroxylamine,Hydrochloride. This was attempted using 
sheep and human immunoglobulins, which were first digested to 
produce F(ab')2 molecules. The sheep IgG (lOmg/ml) was then 
modified with SATA, the human IgG (4mg/ml) was reacted with the 
cross-linker SMPB, and the antibodies were linked as described 
earlier (Method 5.7). After S-200 column chromatography, a
peak was observed at approximately lOOkDa (which corresponds to a 
Fab' sized molecule) followed by a smaller peak at approximately 
5kDa (probably breakdown products). It would appear then, that 
the linkage had either not been successful, or it is possible 
that any conjugated products, being fairly large, could have 
broken down on the journey through the column. The
deprotection stage is designed to free the sulphydryl groups, 
and the success of this reaction can be judged by a yellowing of 
the reaction mixture using Ellman's reagent (according to method 
5.9) which detects the presence of SH groups. This was 
performed on a sample from this stage of the procedure and only a
very slight yellowing of the sample was observed. It is
probable then, that there were not enough -SH groups available 
for the reaction to proceed and this prevented the conjugation of 
the two antibodies from occurring.
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The introduction of -SH groups to proteins was therefore 
attempted as an exercise on its own using lyophilized human IgG, 
but this was never achieved even though the instructions were 
followed to the letter, and time factors prevented the matter 
being pursued further. This method of linking using the SATA 
modification folowed by SMPB conjugation involved a number of 
manipulations which may have adversely affected the antibodies 
being used, and also caused the antibodies to be diluted at each 
stage and this is especially important when the initial 
concentration of the antibodies is low. It was decided, 
therefore, that this method was not practical for the efficient 
preparation of 'bispecific' antibodies.
A second attempt was made to link the chosen antibodies with 0- 
PDM, but the molecular weight of the product was very low (i.e. 
approximately 2KDa) and this would suggest that the sample had 
degraded. The samples were examined at each stage for
sulphydryl content, to check if the reaction was proceeding as 
normal. When the cross-linker was added, the maleimide groups 
should have used up the -SH groups available, and therefore no 
such groups should be detected if the reaction had occurred 
successfully. In this case, however, SH groups were detected 
at this point in the reaction, suggesting that the cross-linker 
was not functioning as it should and it was decided to obtain a 
new batch.
THE USE OF FLOW CYTOMETRY IN THE ANALYSIS OF BISPECIFIC PRODUCTS
Flow Cytometry was chosen to analyse the bispecific products 
and therefore initial experiments to establish the optimum and 
efficient running of the system had to be performed, with 
regards to incubation times and conjugates to be used.
OWmMl cells were used as the target cells for the analysis of the 
binding of the anti-ovarian antibodies(F14A/14C1) and the 
previously prepared SMPB (A-B) product (see earlier text).
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The ovarian cancer antigen-specific component (F14A/14C1) would 
bind to the target cells leaving the mouse component free to be 
detected by an anti-mouse fluorescent conjugate.
Fluorescence would therefore only be observed if a bispecific 
product was present. For example, if the human component was 
present alone then the anti-mouse conjugate would not bind to 
this and fluoresce, and similarly, if the mouse component was 
present alone, it would not be able to bind to the target cells 
initially and no fluorescence would be observed.
The following combinations of antibody and conjugates (whole IgG 
molecule) were analysed for fluorescence according to method 5.18
1. OWmMl alone
2. OWmMl + F14A/14C1 + anti-human FITC conjugate(HFITC)
3. OWmMl + anti-human FITC conjugate
4. OWmMl + IgG + anti-human FITC conjugate
5. OWmMl + SMPB 'bispecific' + anti-mouse FITC conjugate(MFITC)
6. OWmMl + anti-mouse FITC conjugate
All combinations, with the exception of the target cells alone 
(which had a positive population of 1%), produced levels of 
fluorescence in excess of 95% (data not shown). It was observed 
that the conjugates alone were binding to the target cells, and 
were therefore not suitable for any analysis work. As an 
alternative, conjugates were acquired which lacked the Fc 
portion of the molecule i.e. F(ab)'z molecule conjugates, and 
these were used in the analysis as before, and the results shown 
in Table 4.
On this occasion, the F(ab)'z conjugates did not bind with any 
significance to the target cells suggesting that the cell line 
might bear Fc receptors (FcR), since no positive fluorescence 
was observed when the Fc portion of the antibodies were absent. 
It was hoped to test this hypothesis by using the antibodies 
CD16, CD32 and CD64 which would bind to FcRIII, FcRII and FcRI 
respectively,but unfortunately these were not available at the 
time,
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TABLE 4: FLOW CYTOMETRY 1
TEST : % POSITIVE
OWmMl 0.5
OWmMl + 14C1/F14A + HFITC 3.3
OWmMl + HFITC 0.5
OWmMl + IgG + HFITC 38.1
OWmMl + SMPB BISP + MFITC 1.6
OWmMl + MFITC 1.4
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This analysis also demonstrated that neither the SMPB 
'bispecific' product, or the anti-ovarian antibodies alone, 
bound to the target cells with any significance, whilst the 
irrelevant human IgG antibody at the same concentration (isolated 
from serum by protein A affinity chromatography) did. This 
analysis was repeated with similar results (not shown) and it was 
clear that the antibody we were interested in studying, did not 
bind to the target cells as previously reported. It is possible 
that the characteristics of the target cell line had changed over 
a period of time and were no longer expressing antigen 
recognizable by the antibody, or the cell lines producing the 
antibody had become altered in some way, through continuous
culture. This may have been caused by contamination with
Mycoplasma, which is known to contaminate a large number of 
cel 1-lines throuhgout the world. This has been ignored by many 
investigators, but mycoplasma has been shown to alter the 
cell in terms of macromolecular synthesis, stability of genetic 
material, and other parameters including sensitivity to drugs
and viruses [31]. The cell lines used in this investigation 
were tested and shown to be mycoplasma positive, and this may 
have been the reason for the observed results.
As a result of the non-binding of the anti-ovarian cancer 
specific antibodies, it was necessary to check the specificity 
of the 0KT3 antibody, with regards to its target antigen - the 
CD3/TCR complex on T-cells, before proceeding any further. The 
PMBC's were prepared according to method 5.17 and the results of 
a number of different tests are shown in Table 5.
The 0KT3 antibody bound to the PBMCells as expected, and the 
W6/32 antibody (anti-MHC class 1) produced over 90% fluorescence 
with both PBMC and OWmMl target cell lines. This antibody was 
included in the system as a control to ensure that the conjugates 
were binding and fluorescing as they should be (a profile of the 
binding of W6/32 to OWmMl can be seen in Figure 9).
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TABLE 5: FLOW CYTOMETRY 2
TEST ! % POSITIVE
PBMC 0.3
PBMC + MFITC 0.4
PBMC + 0KT3 + MFITC 49.5
PBMC + W6/32 + MFITC 98.2
OWmMl 0.4
OWmMl + W6/32 + MFITC 99.9
OWmMl + IgG + MFITC 1.8
OWmMl + IgG + W6/32 + MFITC 81.1
OWmMl + MFITC 1.9
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FIGURE 9: PROFILE OF W6/32 ANTIBODY BINDING TO OWmMl CELLS
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It was therefore possible to examine the SMPB 'bispecific' 
product by binding the 0KT3 component to PBMC's, which would 
leave the anti-ovarian component free to be detected by an anti­
human FITC conjugate. This was attempted but no measurable 
fluorescence was detected, and therefore it was concluded by 
flow cytometry that this SMPB product did not constitute a 
Bispecific antibody.
In a previous analysis (Table 4) human IgG was shown to bind to 
the OWmMl target cells, but it was not known which receptors 
were involved. Consequently, experiments were performed with 
human IgG to obtain more information on the nature of the
binding. Target cells were pre-incubated with human IgG to see
if this would affect the subsequent binding of W6/32 since this 
produces strong fluorescence.(See Table 5 for results).
There was a slight reduction in the positive population when IgG 
was included in the test(approximately 10%), compared to that 
observed with the W6/32 antibody alone, but this was not greatly 
significant, and it is therefore likely that the IgG was binding 
to a different receptor than the W6/32 antibody. This analysis 
was repeated with similar results (not shown).
Another irrelevant antibody was also tested in the system - A 
mouse anti-toxoplasma antibody which was incubated with the
target cells (OWmMl) alone, and also after pre-incubation with 
human IgG. The positive populations observed were 53% and 47%
respectively (incubation of the conjugate and target cells alone 
being 2.6%). This antibody appeared to bind quite strongly to 
the cell line, but again it was not known which receptors were 
involved but they seemed to be different from those binding the
human IgG since the pre-incubation stage did not affect the
binding with any significance. They could, however, also be 
binding through their Fc-components if there were a large number 
of Fc receptors on the target cell surface.
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To test this hypothesis of binding through the FcR, the binding 
of the F(ab')z fragment of human IgG was compared to that of 
the intact molecule, producing positive fluorescence of 12.6% 
and 58.6% respectively.
This would appear to suggest that the Fc component does have a 
positive role in the binding of the antibody since its removal 
resulted in a decrease in the fluorescence observed.
It would have been useful to test the anti-toxoplasma antibody in 
this manner, to see how the removal of the Fc component affected 
its binding to the target cells, but there was no time available 
to do so.
As alternatives to the anti-ovarian antibodies F14A/14C1, an 
anti-colonic carcinoma antibody (505), and an anti-ovarian 
carcinoma antibody (595), were obtained for use in the 
conjugations with the 0KT3 antibody.
These were analysed against the target cell lines OWmMl, OVAN-4 
and CGLG-320, and the results are presented in Table 6. The 
antibodies bound to their respective cell lines as expected - 595 
to GWmMl and GVAN-4, and 505 to CGLG-320, the latter showing a 
very high positive fluorescence. Antibody 595 also bound to the 
CGLG-320 cell line but with a lower percentage which was probably 
not significant.
A new anti-CD3 antibody (Rat derived) was also acquired because 
the laboratory cell lines were not producing adequate amounts for 
our purposes. This was subjected to flow cytometry against 
PBMCs and fluoresced with a positive population of 72%, which 
was greater than the previous antibody and could therefore be 
used in this investigation.
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TABLE 6: FLOW CYTOMETRY 3
TEST ! % POSITIVE
OWmMl 0.4
OWmMl + MFITC 0.9
OWmMl + 595 + MFITC 53.0
OWmMl + 505 + MFITC 3.0
OVAN-4 0.2
OVAN-4 + MFITC 0.3
OVAN-4 + 595 + MFITC 60.0
OVAN-4 + 505 + MFITC 1.4
COLO-320 0.1
COLO-320 + MFITC 0.2
COLO-320 + 595 + MFITC 14.1
COLO-320 + 505 + MFITC 98.0
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CROSS-LINKING WITH SPDP
A third cross-linker - SPDP, was chosen to link the new 
antibodies. Rat anti-CD3 antibody (4mg total) and the 595 
antibody (4.2mg total) were concentrated to 0.1ml before the 
addition of 0.9ml coupling buffer to each. Intact antibodies 
were used in this instance, to keep to a minimum, the number of 
manipulations carried out . The reaction continued as described 
in method 5.6, and the resulting product was passed through a 
column of Ultrogel AcA34. This was used because it has an 
exclusion limit of 300KDa, and this was approximately the size 
of the desired 'bispecific' product. The first peak observed 
corresponded to a molecular weight of approximately 250Kda, 
whilst the second approximated to a very small molecular weight. 
The first product was slightly less in terms of molecular weight 
than was expected for a 'bispecific' product, but this may have 
been due to the disassociation of one of the light chains from 
the complex. The product was then concentrated to approximately 
1ml in PBS (0.4mg/ml) and stored for further experimentation. 
The recovery of the product was approximately 5% of the initial 
antibody available.
Analysis of this product before (SPDP B) and after (SPDP A) 
column chromatography was carried out by flow cytometry and 
produced the results shown in Table 7.
Initial binding studies then appeared to demonstrate that a 
'bispecific' product had been produced, since the positive 
fluorescence was quite significant compared to the control tests. 
The reduced fluorescence observed in the linkage after it had 
been subjected to column chromatography is consistent with the 
digestion mixture being 'cleaned up', leaving only one major 
product.
The products were also analysed against PBMCs to see if the 
conjugation process had affected the binding site of the other 
antibody, and the results are presented in Table 8.
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TABLE 7: FLOW CYTOMETRY 4
TEST ! % POSITIVE
OVAN-4 0.1
OVAN-4 + RFITC 8.5
OVAN-4 + SPDP B + RFITC 65.0
OVAN-4 + SPDP A + RFITC 34.0
TABLE 8: FLOW CYTOMETRY 5
TEST 1 % POSITIVE
PBMC 0.1
PBMC + MFITC 2.7
PBMC + SPDP B + MFITC 50.1
PBMC + SPDP A + MFITC 77.2
PBMC + W6/32 + MFITC 99.3
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Again the 'bispecific'products showed a high positive 
fluorescence compared to the controls, but this time the greater 
percentage was observed in the link that had been subjected to 
column chromatography.
Analysis of the products with the OVAN-4 target cel 1-lines was 
repeated and the results are shown in Table 9. This presented 
the question of the specificity of the anti-rat conjugate, which 
bound to the mouse 595 antibody with approximately the same 
efficiency as the anti-mouse conjugate, but cross-reactivity 
between rat and mouse components is to be expected.
Because of the design of the test, if specific fluorescent 
conjugates are used for the different antibody components 
involved, then any fluorescence observed with 'bispecific' 
products usually confirms that the linkage has been successful.
In this case, fluorescence was indeed observed with the 
'bispecific' products, but one of the fluorescent conjugates 
used was shown to bind to both antibody components. However, 
the fluorescence observed with the 'bispecific' products was 
greater than that observed with the conjugates and single 
antibody alone, and therefore the product probably was in fact a 
'bispecific' antibody.
If this is true then the 'bispecific' antibody, should be able 
to direct effector cells to ovarian cancer target cells in a 
cytotoxicity assay and lead to their destruction. Method 5.16 
describes how the assay was set up.
OVAN-4 cells (Target - T) were used in the assay in combination 
with the 'bispecific' antibody (SPDP - A) at various 
concentrations, and effector cells (PBMC - E) at two 
effector:target ratios. Four plates were set up. Two plates were 
incubated with non-activated PBMC's for 4 and 24 hours, and two 
were incubated with activated PBMC's ( cultured with 500units/ml 
IL-2 for 48 hours) for 4 and 24 hours, and the results of 
specific cytotoxicity(%) are presented in tables 10-13.
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TABLE 9: FLOW CYTOMETRY 6
TEST ! % POSITIVE
OVAN-4 0.1
OVAN-4 + RFITC 3.2
OVAN-4 + MFITC 2.8
OVAN-4 + SPDP B + RFITC 79.7
OVAN-4 + SPDP A + RFITC 62.2
OVAN-4 + 595 + MFITC 52.6
OVAN-4 + 595 + RFITC 49.6
OVAN-4 + W6/32 + MFITC 91.0
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In the assay, each test, apart from those containing PBS (as 
stated in the tables) was performed in medium(MED).
The PBS controls were included as a comparison, and demonstrated 
that on average, the medium did not have an adverse on the cells.
In Table 10, the tests containing the neat and 1:2 antibody 
dilution of the 'bispecific' antibodies did not produce any 
measurable chromium release at all, and therefore, did not
appear to have directed any specific cytotoxicity towards the
target cells. The test with the 1:4 antibody dilution did 
produce a small amount of cytotoxicity but this was less than
that of the control without antibody present (in MED) and was not
regarded as significant.
When the radioactivity was measured after an incubation period of 
24 hours, and the percentage cytotoxicity calculated, the 
figures were much higher in most cases (Table 11), compared to 
the respective tests after 4 hours. Again, the neat and 1:2
antibody dilution tests produced little or no cytotoxicity 
towards the target cells, whereas the 1:4 antibody dilution did. 
This was higher than that observed in the test sample without 
antibody (in MED) by approximately 50% at both effector:target 
cell ratios.
This could therefore be an indication of the presence of 
'bispecific' antibody, able to direct the specific killing of 
target cells.
In Tables 12 and 13, activated effector cells were used in the 
assay and similar results were obtained, that is, in those tests 
where cytotoxicity was observed the figures were greater after 24 
hours than after 4 hours. In addition, the values were much 
higher than those observed with the non-activated effector cells.
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TABLE 10: CYTOTOXICITY ASSAY 1
NON-ACTIVATED PBMC : AFTER 4 HOURS
TEST : % CYTOTOXICITY
T + MED + E 40:1 28.0
T + MED + E 20:1 9.9
T + PBS + E 40:1 11.1
T + PBS + E 20:1 6.7
T + SPDP A(N) + E 40:1 0.0
T + SPDP A(N) + E 20:1 0.0
T + SPDP A(l/2) + E 40:1 0.0
T + SPDP A (1/2) + E 20:1 0.0
T + SPDP A (1/4) + E 40:1 10.5
T + SPDP A (1/4) + E 20:1 2.3
-
TABLE 11: CYTOTOXICITY ASSAY 2
NON-ACTIVATED PBMC : AFTER 24 HOURS
% CYTOTOXICITY
T + MED + E 40:1 29.0
T + MED + E 20:1 20.6
T + PBS + E 40:1 55.0
T + PBS + E 20:1 33.6
T + SPDP A(N) + E 40:1 0.0
T + SPDP A(N) + E 20:1 11.8
T + SPDP A(l/2) + E 40:1 0.0
T + SPDP A (1/2) + E 20:1 0.0
T + SPDP A (1/4) + E 40:1 48.5
T SPDP A (1/4) + E 20:1 40.2
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TABLE 12 : CYTOTOXICITY ASSAY 3
ACTIVATED PBMC : AFTER 4 HOURS
TEST : % CYTOTOXICITY
T + MED + E 40:1 49.0
T + MED + E 20: 1 33.2
T + PBS + E 40:1 43.8
T + PBS + E 20:1 34.0
T + SPDP A(N) + E 40:1 0.0
T + SPDP A(N) + E 20:1 0.0
TABLE 13 : CYTOTOXICITY ASSAY 4
ACTIVATED PBMC : AFTER 24 HOURS
TEST : % CYTOTOXICITY
T + MED + E 40:1 79.0
T + MED + E 20:1 61.4
T + PBS + E 40:1 74.0
T + PBS + E 20:1 60.6
T + SPDP A(N) + E 40: 1 74.6
T + SPDP A(N) + E 20:1 79.0
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The neat antibody did not increase the cytotoxic effect of the 
effector cells alone after 24 hours, and no chromium was 
released at all after 4 hours, but this was consistent with the 
results obtained from the same tests using non-activated PBMC's. 
If antibody at the different dilutions had been included in this 
assay, they may also have resulted in the increased cytotoxicity 
observed in Table 11, since it is possible that antibody at too 
high a concentration leads to cross-linking, preventing the 
effector cells from binding and exerting a cytotoxic effect.
Therefore, non-activated PBMCs did appear to have directed some 
cytotoxicity against the target cells and this was enhanced when 
the antibody (1:4) was included in the assay, suggesting that it 
was 'bispecific' in nature.
ANALYSIS OF PRODUCTS USING SDS-PAGE
SDS-PAGE was performed on samples from the various stages of 
this SPDP-linkage to obtain an estimate of their molecular 
weights, and this would give an indication as to whether the 
linkage had been carried out successfully. The following 
samples were subjected to SDS-PAGE and the resulting pattern of 
bands can be seen in Figure 10 .
Lane 1. Molecular weight markers
Lane 2. Human IgG
Lane 3. 595 antibody
Lane 4. Rat CD3 antibody
Lane 5. Bispecific before1 chromatography (SPDP B)
Lane 6. Bispecific after passage through Ultrogel
Lane 7. Bispecific after passage through S-200
Lane 8. Molecular weight markers
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MOLECULAR WEIGHT
MARKERS
150K-
50K-
-205K
-116K
-97K
-66K
-45K
-29K
LANE
FIGURE 10: SDS-POLYACRYLAMIDE GEL STAINED WITH COOMASSIE BLUE
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Human IgG produced a band at approximately ISOKDa as expected, 
but the 595 antibody produced a band at 50 KDa. This is the size 
of the heavy chain of IgG antibody but it is possible that the 
antibody light chains had dissociated during the preparation 
stages for SDS-PAGE. The literature suggests that samples 
should be boiled with a reducing agent to dissociate the proteins 
into individual polypeptides which bind to the SDS. The proteins 
become negatively charged and they will migrate through the gel 
according to their molecular weight.
We however, wished to obtain an estimate of the molecular weight 
of the intact structure of each antibody and therefore did not 
use a reducing agent in the sample buffer and only heated the 
samples to approximately 60°C. The effect of heating the samples 
beyond this to boiling can be seen in Figure 11.
Molecular weight markers 
Human IgG 
595 antibody 
Rat anti-CD3 antibody 
SPDP B prepared as normal 
SPDP B prepared at R.T.
SPDP B prepared by boiling 
Lane 8. Molecular weight markers
Lane 1
Lane 2
Lane 3
Lane 4
Lane 5
Lane 6
Lane 7
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MOLECULAR WEIGHT
MARKERS
150K-
50K-
-205K
-116K
-97K
-66K
-45K
-29K
LANE 1 2 3 4 5 6 7 8
FIGURE 11: SDS-POLYACRYLAMIDE GEL STAINED WITH COOMASSIE BLUE
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This clearly demonstrated that boiling samples in loading buffer 
was not appropriate for our purposes since this resulted in the 
dissociation of the antibody into its individual components (as 
seen in lane 7).
The large band present in lanes 5,6 and 7 of both gels is due to 
the presence of BSA which was added to stabilize the products. 
Also in these lanes, bands can be seen just entering the 
resolving gel, and these may represent high molecular weight 
products such as the bispecific antibodies. The Rat anti-CD3 
antibody produced a band at approximately 150Kda as expected 
(lane 4), but there appeared to have been an excess of 595 
antibody loaded onto the gel producing the smear seen in lane 3.
Because high molecular weight products were observed on both gels 
the bispecific products were analysed once more against the OVAN- 
4 cell line, and the results presented in Table 14. SPDP-B 
and SPDP-A produced high levels of fluorescence as before. 
However, when the mouse 595 antibody was probed with the anti-rat 
fluorescent conjugate (RFITC), and the rat anti-CD3 antibody was 
probed with the anti-mouse conjugate high levels of fluorescence 
were also observed. Once again, cross-reactivity would appear to 
be the problem and it was therefore not possible to conclude 
that the product was a 'bispecific' antibody by flow cytometry 
using these conjugates.
In this test the anti-CD3 antibody was also shown to bind to the 
OVAN-4 target cells which was not expected, and this test was 
repeated with similar results (not shown). This test also 
included PBMC's as the target cells and compared the binding of 
the CD3 antibody using the anti-mouse and anti-rat conjugates as 
probes. In this case higher levels of fluorescence were 
observed with the anti-mouse conjugate than with the specific 
anti-rat conjugate(81.6% and 37.7% respectively). Again, these 
conjugates could not be used to reliably analyse the 'bispecific' 
conjugates prepared.
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TABLE 14: FLOW CYTOMETRY 7
TEST 1 % POSITIVE
OVAN-4 0.2
OVAN-4 + RFITC 2.6
OVAN-4 + MFITC 3.7
OVAN-4 + SPDP B + RFITC 95.7
OVAN-4 + SPDP A 4- RFITC 94.8
OVAN-4 + 595 + MFITC 96.6
OVAN-4 + 595 + RFITC 80.4
OVAN-4 + CD3 + RFITC 93.0
OVAN-4 + CD3 + MFITC 87.8
7?
It was proposed that another linkage be attempted using a new 
batch of 0-PDM. Irrelevant antibodies were again used in the 
initial experiments to preserve stocks of specific antibodies. 
Human IgG was digested with pepsin to produce F(ab')a antibody 
and then reduced with 2-ME to produce two Fab' components. One 
of the Fab' components was reacted with the cross-linker 
dissolved in DM50 (the protocol according to Glennie et al [22] 
used dimethy1formamide, but this caused precipitation of the 
antibody solution in this case and was therefore not suitable) 
and was then added to the unreacted Fab' component. After 
concentration and incubation overnight at 4°C, the mixture was 
subjected to column chromatography(5-200) and this produced a 
large peak approximating to 80KDa and a smaller peak 
corresponding to low molecular weight products.
The reaction was followed using Ellmans reagent to check for the 
presence of sulphydryl groups and this suggested that the 
reaction had been carried out successfully. The products of the 
linkage were subjected to 5D5-PAGE and the results are presented 
in Figure 12.
Lane 1. Molecular weight markers
Lane 2. Human IgG
Lane 3. Human IgG F(ab')z molecule
Lane 4. F(ab')2 + 2-ME
Lane 5. Bispecific after 5-200 (peak 1)
Lane 6. Bispecific after 5-200 (peak 2)
Lane 7. Molecular weight markers
Human IgG produced a band at approximately ISOKDa, and the 
F(ab')2 molecule appeared to be lower down at approximately
120KDa, confirming that the pepsin digestion had been successful.
The F(ab')2 molecule was then subjected to reduction by 2-ME in 
the linking procedure and a band was seen at 50KDa in lane 4, 
which was the size of the expected product.
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MOLECULAR WEIGHT
MARKERS
150K-
50K-
-205K
-116K
-97K
-66K
-45K
-29K
LANE
FIGURE 12 : SDS-POLYACRYLAMIDE GEL STAINED WITH COOMASSIE BLUE
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The resulting linkage mixture after passage through sephacryl S-
200 produced two peaks (run in lanes 5 and 6). There did not
appear to be any bands in lane 6 (peak 2) but the products were
estimated to be of low molecular weights than the standards and
had probably run off the gel. In lane 5, a band can be seen at 
the 50KDa level (size of a Fab' molecule) and at the ISOKDa 
level, and this suggested that the antibodies had conjugated. 
The 0-PDM cross-linker then, appeared to be able to link 
antibodies successfully and was therefore considered suitable for 
further investigation.
Before any attempts were made to link the antibodies of interest 
it was again necessary to check their specificity with respect to 
their target cell lines. In a previous test (Table 14), anti- 
CD3 antibody had been shown to bind to the OVAN-4 cell line with 
a high positive population. This test was therefore repeated with 
different combinations of anti-CD3 and human IgG to see how this 
affected its binding to the cell line. The results in Table 15 
indicate that pre-incubating the cell line with anti-CD3 before 
incubating with IgG, reduced the binding of the IgG by only a 
small percentage. Controls were included to ensure that any 
values of binding observed, would be attributed to the antibody 
in question and not to conjugates binding to cell lines, or to 
antibodies used in pre-incubating stages binding to the 
conjugates. Human IgG would therefore appear to bind to a 
different site than that used by the anti-CD3. In a similar
test, the cells were incubated with human IgG as the primary 
antibody followed by antiCD3 and the anti-rat conjugate, 
producing a positive fluorescence of 55.4%. This test run
however did not include the CD3 incubated with the cells alone 
for a comparison. The above test was therefore repeated to 
include this control and the results presented in Table 16.
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TABLE 15: FLOW CYTOMETRY 8
TEST % POSITIVE
OVAN-4 0.1
OVAN-4 + HFITC 2.6
OVAN-4 + IgG + HFITC 51.3
OVAN-4 + CD3 + IgG + HFITC 43.2
OVAN-4 + CD3 + HFITC 6.2
OVAN-4 + RFITC 2.7
OVAN-4 + IgG + RFITC 1.5
OVAN-4 + IgG + CD3 + RFITC 55.4
16: FLOW CYTOMETRY 9
TEST % POSITIVE
OVAN-4 0.1
OVAN-4 + HFITC 3.2
OVAN-4 + IgG + HFITC 21.4
OVAN-4 + CD3 + IgG + HFITC 20.1
OVAN-4 + CD3 + HFITC 3.4
OVAN-4 + RFITC 3.2
OVAN-4 + IgG + RFITC 4.8
OVAN-4 + CD3 + RFITC 52.0
OVAN-4 + IgG +CD3 + RFITC 19.9
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The results were similar to that observed previously except that 
the percentages were lower but this was probably due to the fact 
that fewer target cells were present initially. However, the 
inclusion of the anti-CD3 antibody alone appeared to indicate 
that pre-incubation of the cells with IgG did reduce the binding 
of the CD3 to the cell line and this would suggest a similar 
binding site, such as the Fc receptor on the tumour cell surface.
On the other hand, if a high concentration of IgG antibody had 
been present, cross-linking might have occurred which may have 
obscured other binding sites and prevented the anti-CD3 from 
attaching. The fact that this antibody was binding to the 
target cell line at all meant that any bispecific products 
produced containing this antibody could not be analysed as 
before. This is because, to use Flow Cytometry to check for the 
presence of 'bispecific' antibodies, each antibody must be 
specific for a different target to allow specific conjugates to 
bind and fluoresce. Further characterization of this cell line 
and the binding sites involved could not be undertaken because of 
limited time and many questions were thus left unanswered.
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SUMMARY
This investigation was designed to look at the construction of 
bispecific antibodies using three different cross-linkers - SMPB, 
SPDP and 0-PDM.
Conjugation with SMPB involved a number of manipulations and was 
not considered to be practical for routine use.
SPDP produced a molecule which was the correct size for a 
bispecific antibody and flow cytometry analysis demonstrated its 
binding to the target cells. The fluorescent conjugates
available however, were discovered not to be specific for the 
antibodies in question and the fluorescence observed could not be 
taken as being solely due to the presence of 'bispecific' 
antibodies. Further cytotoxicity testing of the product did
however produce some evidence that the antibody was in fact 
'bispecific' in nature.
The third cross-linker, 0-PDM, also appeared to be successful, 
cross-linking two human IgG Fab' fragments but unfortunately
time factors prevented the process being repeated with the 
antibodies of interest. If time had been available, and 
'bispecifics' of 595/0KT3 had been successfully produced, these 
would have been analysed by Flow Cytometry and cytotoxicity 
assays to see if they had lost any specificity or activity as a 
result of the linking process.
This investigation also raised a number of questions on the 
specificity of the antibodies involved. The previously defined 
antibody 14C1 no longer bound to the ovarian target cell line, 
while irrelevant antibodies did bind with relatively high 
percentages of fluorescence. This binding however, was thought 
to be due to the presence of Fc receptors on the surface of the 
target cell lines, since antibodies lacking the Fc component did
not bind as well as the intact molecules.
80
The linking procedures with SMPB and 0-PDM proved to be time 
consuming, labour intensive and difficult to perform on a 
routine basis. The SPDP process was fairly straight forward, 
and out of the three would be the method of choice if linking had 
to be carried out regularly.
The lack of antibody also meant that conjugation procedures were 
not being carried out at their optimum levels and if more 
antibody had been available the linkages might have been carried 
out more successfully.
Other investigators have, successfully linked different 
antibodies together by chemical means. Glennie et al, [22] in
particular has produced bispecific antibodies without much 
trouble, linking mouse/mouse antibodies and mouse/rabbit 
antibodies. In this investigation however, we were trying to 
link mouse/rat and mouse/human antibodies and this may have been 
the reason for the difficulties encountered.
Glennie and collaborators [30] have even gone a step further in 
terms of chemical linkages with the production of Trispecific 
antibodies. Tumour targeting with antibody derivatives requires 
activated effector cells, since even with the appropriate 
bispecific antibody, unprimed T-cells and monocytes are only 
minimally cytotoxic to tumour targets. Activation with IL-2 
causes problems, because in vivo it acts locally and its 
systemic use in patients can be inefficient. Used at the levels 
required for activation it can lead to severe and life 
threatening side effects. The alternative, it is suggested, 
is to use trispecific antibodies which can activate T-cells using 
co-operative signalling via two Fab' arms and retarget through 
the third arm. They are completely stable to reduction and are 
near IgG size, mediating highly efficient lysis of tumour cells 
using fresh unprimed PBMC.
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To produce the trispecific version, bispecific antibodies are 
prepared according to the 0-PDM protocol , and then linked to a 
FAb'(MAL) from a third antibody, and these have been suggested 
for use as a more suitable alternative to the much studied 
'bispecific' antibodies.
Whether 'bispecific' or 'trispecific' antibodies fulfil their 
potential as alternatives to the conventional therapies has yet 
to be seen, but it does seem likely that their influence on 
immunotherapy will not be as much as had been hoped, for the 
reasons stated in this investigation.
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